Hematuria differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 15: Line 15:
! colspan="3" rowspan="5" |Diseases
! colspan="3" rowspan="5" |Diseases
| colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
Line 22: Line 22:
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|-
|-
! colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Low back pain
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Low back pain
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nausea/Vomiting
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nausea/
Vomiting
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary symptoms
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary symptoms
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hypertension
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hypertension
Line 40: Line 41:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Frequency
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Frequency
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Oliguria
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Oliguria
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Light microscopy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Light microscopy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunoflourescence pattern
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunoflourescence pattern
|-
|-
| rowspan="42" style="background: #DCDCDC; padding: 5px; text-align: center;" |Hematuria
| rowspan="47" style="background: #DCDCDC; padding: 5px; text-align: center;" |Hematuria
| rowspan="8" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Glomerular disease|Glomerular diseases]]
| rowspan="9" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Glomerular disease|Glomerular diseases]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[IgA nephropathy|IgA nephropathy (Berger nephropathy)]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[IgA nephropathy|IgA nephropathy (Berger nephropathy)]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 55: Line 56:
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| colspan="2" style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Electron microscopy shows mesangial hypercellularity and increased mesangial matrix
* Electron microscopy shows mesangial hypercellularity and increased mesangial matrix
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Focal or diffuse mesangial proliferation
* Focal or diffuse mesangial proliferation
* Extracellular matrix expansion
* Extracellular matrix expansion
Line 81: Line 82:


* Hearing loss
* Hearing loss
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Pyuria]]
* [[Pyuria]]
* Red cell [[casts]]
* Red cell [[casts]]
Line 90: Line 91:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* High-frequency sensorineural hearing loss
* High-frequency sensorineural hearing loss
| colspan="2" style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of type IV collagen
* Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of type IV collagen
Line 112: Line 113:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Urine samples for protein and blood
* Urine samples for protein and blood
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Renal Biopsy
Renal Biopsy
Line 124: Line 124:
* Endothelial and mesangial cells and migrant inflammatory cells
* Endothelial and mesangial cells and migrant inflammatory cells
* Hyaline droplets
* Hyaline droplets
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Immunoglobulin G and C3 in a diffuse granular pattern
* Immunoglobulin G and C3 in a diffuse granular pattern
Line 151: Line 150:
* Hepatitis B or C infection
* Hepatitis B or C infection
* Antineutrophil cytoplasmic antibody titers, serum protein electrophoresis
* Antineutrophil cytoplasmic antibody titers, serum protein electrophoresis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Shrunken kidneys
* Shrunken kidneys
Line 158: Line 156:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Segmental solidification in the perihilar region and  peripheral areas, specially the tubular pole
* Segmental solidification in the perihilar region and  peripheral areas, specially the tubular pole
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Coarsely granular deposits of IgM and C3
* Coarsely granular deposits of IgM and C3
Line 186: Line 183:
* Eleated LDH and CPK
* Eleated LDH and CPK
* Proteinuria  
* Proteinuria  
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |Diffuse, proliferative, necrotizing glomerulonephritis with crescent formation
| style="background: #F5F5F5; padding: 5px;" |Diffuse, proliferative, necrotizing glomerulonephritis with crescent formation
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |Biospy
| style="background: #F5F5F5; padding: 5px;" |Biospy
Line 214: Line 209:
* Cellular casts
* Cellular casts
* Low iron
* Low iron
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
Line 225: Line 218:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thin basement membrane disease]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thin basement membrane disease]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 245: Line 236:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fabry's disease|Fabry disease]]
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fabry's disease|Fabry disease]]
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
Line 258: Line 249:
* Hematuria
* Hematuria
* Proteinuria
* Proteinuria
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |Non-specific+/- nephrotic picture
| style="background: #F5F5F5; padding: 5px;" |Non-specific+/- nephrotic picture
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
|-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
|-
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tubulointerstitial diseases of the kidney|Tubulointerstitial diseases]]
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tubulointerstitial diseases of the kidney|Tubulointerstitial diseases]]
Line 283: Line 290:
* [[Pyuria]]
* [[Pyuria]]
* [[Microscopic hematuria]]
* [[Microscopic hematuria]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 290: Line 296:
* Non-enhanced lesions surrounded by rings of excreted contrast material
* Non-enhanced lesions surrounded by rings of excreted contrast material
* Hyperattenuated [[medullary]][[Calcification|calcifications]]
* Hyperattenuated [[medullary]][[Calcification|calcifications]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 301: Line 306:
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 319: Line 322:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Analgesic]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Analgesic]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 340: Line 341:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephrolithiasis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephrolithiasis]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 361: Line 360:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Reflux nephropathy|Reflux nephropathy (hydronephrosis)]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Reflux nephropathy|Reflux nephropathy (hydronephrosis)]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 381: Line 378:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Malignancy]]
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Malignancy]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Renal cell carcinoma|Renal cell carcinoma (RCC)]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Renal cell carcinoma|Renal cell carcinoma (RCC)]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 404: Line 399:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephroblastoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephroblastoma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 425: Line 418:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Transitional cell carcinoma|Transitional cell carcinoma (TCC)]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Transitional cell carcinoma|Transitional cell carcinoma (TCC)]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 445: Line 436:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Prostate cancer]]
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Prostate cancer]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 465: Line 454:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Familial|Familial diseases]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Familial|Familial diseases]]
Line 480: Line 487:
* Palpable [[abdominal]] [[mass]] in the [[lumbar]] quadrant
* Palpable [[abdominal]] [[mass]] in the [[lumbar]] quadrant
* [[Palpable]] [[nodular]] [[hepatomegaly]]
* [[Palpable]] [[nodular]] [[hepatomegaly]]
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Hypocitraturia]] in 65% on patients
* [[Hypocitraturia]] in 65% on patients
* [[Hyperuricemia]] in 20% of patients
* [[Hyperuricemia]] in 20% of patients
Line 498: Line 505:
* Non-canonical [[splice]] site alterations
* Non-canonical [[splice]] site alterations
* Combined [[missense]] changes
* Combined [[missense]] changes
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Interstitial fibrosis
* Interstitial fibrosis
* Tubular atrophy
* Tubular atrophy
Line 522: Line 529:
* Abdominal pain
* Abdominal pain
* Acute in onset
* Acute in onset
| colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
* Elevation in serum lactate dehydrogenase
* Elevation in serum lactate dehydrogenase
* Cholesterol levels for hypercholesterolemia
* Cholesterol levels for hypercholesterolemia
Line 532: Line 539:
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
* '''Renal venography:''' Gold standard  
* '''Renal venography:''' Gold standard  
| colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 555: Line 562:
* [[Unintentional weight loss]]
* [[Unintentional weight loss]]
* [[Muscle aches]]
* [[Muscle aches]]
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Complete blood count|CBC]] may show:
* [[Complete blood count|CBC]] may show:
** Leukocytosis
** Leukocytosis
Line 564: Line 571:
* [[Erythrocyte sedimentation rate|ESR]] and [[C-reactive protein]]
* [[Erythrocyte sedimentation rate|ESR]] and [[C-reactive protein]]
* Hepatitis B surface antigen and hepatitic C serologies
* Hepatitis B surface antigen and hepatitic C serologies
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 583: Line 589:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 603: Line 608:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 613: Line 617:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urinary system|Lower urinary tract diseases]]
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urinary system|Lower urinary tract diseases]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Benign prostatic hyperplasia]]
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Benign prostatic hyperplasia]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 624: Line 628:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 633: Line 636:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urolithiasis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urolithiasis]]
Line 644: Line 665:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 664: Line 684:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 684: Line 703:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 705: Line 723:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 725: Line 742:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 745: Line 761:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 765: Line 780:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 785: Line 799:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 795: Line 808:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| rowspan="8" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Infectious disease|Infectious diseases]]
| rowspan="9" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Infectious disease|Infectious diseases]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pyelonephritis]]
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pyelonephritis]]
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
Line 808: Line 821:
* [[Delirium]]
* [[Delirium]]
* [[Headache]]
* [[Headache]]
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Positive  [[leukocyte esterase]] test and [[nitrite test]].
* Positive  [[leukocyte esterase]] test and [[nitrite test]].
* Blood/urine cultures
* Blood/urine cultures
Line 820: Line 833:
Contrast nephrograms
Contrast nephrograms
* Focal areas of striated or wedge-shaped [[hypoperfusion]]
* Focal areas of striated or wedge-shaped [[hypoperfusion]]
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
*[[Neutrophils]]
*[[Neutrophils]]
*Interstitial fibrosis
*Interstitial fibrosis
Line 827: Line 840:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cystitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cystitis]]
Line 840: Line 871:
* [[Dyspareunia]]
* [[Dyspareunia]]
* Supra pubic tenderness
* Supra pubic tenderness
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Pyuria]]: > 5-10 WBC/hpf or 27 [[WBC]]/microliter
* [[Pyuria]]: > 5-10 WBC/hpf or 27 [[WBC]]/microliter
* Positive  [[leukocyte esterase]] test and [[nitrite test]].
* Positive  [[leukocyte esterase]] test and [[nitrite test]].
Line 853: Line 884:
* [[Hydronephrosis]]
* [[Hydronephrosis]]
* [[Calcification]]
* [[Calcification]]
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 869: Line 900:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Body aches
* Body aches
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Increased [[leukocytes]] (>10 per high power field) on CBC
* Increased [[leukocytes]] (>10 per high power field) on CBC
* Bacteria seen on [[urine culture]]
* Bacteria seen on [[urine culture]]
Line 880: Line 911:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Hyperintense lesions on MRI
* Hyperintense lesions on MRI
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Neutrophils]]  
* [[Neutrophils]]  
* Between the epithelial cells or inside the stroma.
* Between the epithelial cells or inside the stroma.
Line 898: Line 929:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Urethral discharge
* Urethral discharge
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Mucoid, [[mucopurulent]], or [[purulent]] [[discharge]]  
* Mucoid, [[mucopurulent]], or [[purulent]] [[discharge]]  
* [[Gram staining|Gram stain]] of urethral secretions demonstrating ≥2 [[WBC]] per field
* [[Gram staining|Gram stain]] of urethral secretions demonstrating ≥2 [[WBC]] per field
Line 908: Line 939:
* Periureteric or perinephric fat stranding.
* Periureteric or perinephric fat stranding.
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 921: Line 951:
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 936: Line 964:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cytomegalovirus]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cytomegalovirus]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 957: Line 983:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Infectious mononucleosis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Infectious mononucleosis]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 978: Line 1,002:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Condylomata acuminata]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Condylomata acuminata]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,000: Line 1,022:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urogenital|Urogenital trauma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urogenital|Urogenital trauma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Inserted [[bladder]] or [[Ureteral disease|ureteral catheters]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Inserted [[bladder]] or [[Ureteral disease|ureteral catheters]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,020: Line 1,040:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Drugs]]
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Drugs]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Anticoagulants]]
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Anticoagulants]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,042: Line 1,060:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| rowspan="14" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dark urine]]
|
| rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemoglobinuria]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
| rowspan="15" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dark urine]]
| rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemoglobinuria]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Autoimmune hemolytic anemia]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Autoimmune hemolytic anemia]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,066: Line 1,100:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Microangiopathic hemolytic anemia]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Microangiopathic hemolytic anemia]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,087: Line 1,119:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thrombotic thrombocytopenic purpura]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thrombotic thrombocytopenic purpura]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,108: Line 1,138:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Paroxysmal nocturnal hemoglobinuria]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Paroxysmal nocturnal hemoglobinuria]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,129: Line 1,157:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Paroxysmal cold hemoglobinuria]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Paroxysmal cold hemoglobinuria]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,149: Line 1,175:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Malaria|Falciparum malaria]]
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Malaria|Falciparum malaria]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,169: Line 1,193:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
|-
| rowspan="8" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Myoglobinuria]]
| rowspan="8" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Myoglobinuria]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Crush injury]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Crush injury]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,193: Line 1,233:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Physical exercise|Vigorous muscle exercise]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Physical exercise|Vigorous muscle exercise]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,214: Line 1,252:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hyperthermia|Hyperthermia (Heat stroke)]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hyperthermia|Hyperthermia (Heat stroke)]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,235: Line 1,271:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Electric shock]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Electric shock]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,256: Line 1,290:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Prolonged [[seizure]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Prolonged [[seizure]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,277: Line 1,309:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Polymyositis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Polymyositis]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,298: Line 1,328:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Trichinosis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Trichinosis]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,319: Line 1,347:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Haff disease]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Haff disease]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 15:18, 23 July 2018

Hematuria Microchapters

Home

Patient Information

Overview

Definition

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hematuria from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hematuria differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hematuria differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hematuria differential diagnosis

CDC on Hematuria differential diagnosis

Hematuria differential diagnosis in the news

Blogs on Hematuria differential diagnosis

Directions to Hospitals Treating Hematuria

Risk calculators and risk factors for Hematuria differential diagnosis

Steven C. Campbell, M.D., Ph.D. Associate Editor(s)-in-Chief: Venkata Sivakrishna Kumar Pulivarthi M.B.B.S [1] Omer Kamal, M.D.[2

Overview

Gross hematuria(GH) must be distinguished from pigmenturia, which may be due to endogenous sources (e.g., bilirubin, myoglobin,and porphyrins), foods ingested (e.g., beets and rhubarb), drugs (e.g., phenazopyridine), and simple dehydration. This distinction can be made easily by urinalysis with microscopy. Notably, myoglobinuria and other factors can cause false-positive chemical tests for hemoglobin, so urine microscopy is required to confirm the diagnosis of hematuria. GH also must be distinguished from vaginal bleeding in women, which usually can be achieved by obtaining a careful menstrual history, collecting the specimen when the patient is not having menstrual or gynecologic bleeding, or, if necessary, obtaining a catheterized specimen. GH may also be detected by the presence of blood spotting on the undergarments of incontinent patients. After ruling out vaginal bleeding and mimics of hematuria, a urologic source must be suspected.

Differential Diagnosis

Hematuria should be differentiated from other disease which mimic hematuria especially hemoglobinuria and myoglobinuria which are dipstick positive but negative for microscopy.

Hematuria differential diagnosis

Differentiating the diseases that can cause hematuria:

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Low back pain Fever Nausea/

Vomiting

Urinary symptoms Hypertension Pitting edema Other Ultrasonography CT scan Other
Dysuria Frequency Oliguria Light microscopy Immunoflourescence pattern
Hematuria Glomerular diseases IgA nephropathy (Berger nephropathy) + - - - + + + - - - -
  • Electron microscopy shows mesangial hypercellularity and increased mesangial matrix
  • Focal or diffuse mesangial proliferation
  • Extracellular matrix expansion
  • IgA deposited in a diffuse granular pattern in the mesangium
Biopsy -
Hereditary nephritis (Alport syndrome) - - - - - - + -
  • Cataract
  • Hearing loss
  • Shrunken kidneys
-
  • High-frequency sensorineural hearing loss
-
  • Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of type IV collagen
  • Genetic Analysis
-
Poststreptococcal glomerulonephritis +/- + - - + + + +
  • Edema
  • Anemia
  • Increased Blood Pressure
  • Urine samples for protein and blood

Renal Biopsy

  • Irregularly thin and attenuated GBM
  • Splitting of GBM
  • Scarring
- -
  • Hypercellularity of the glomeruli
  • Endothelial and mesangial cells and migrant inflammatory cells
  • Hyaline droplets
  • Immunoglobulin G and C3 in a diffuse granular pattern
  • Starry sky pattern
Biopsy -
Focal segmental glomerular sclerosis - - - - - - + +
  • Nephrotic syndrome
  • ESRD
  • Pleural effusion
  • Ascites
  • Abdominal pain
  • Urinalysis reveals large amounts of protein, along with hyaline and broad waxy casts
  • Hepatitis B or C infection
  • Antineutrophil cytoplasmic antibody titers, serum protein electrophoresis
  • Shrunken kidneys
- -
  • Segmental solidification in the perihilar region and peripheral areas, specially the tubular pole
  • Coarsely granular deposits of IgM and C3
Biopsy -
Rapidly progressive glomerulonephritis + + + - - - + -
  • Abdominal pain
  • Painful cutaneous nodules
  • Migratory polyarthropathy
  • Sinusitis
  • Cough
  • Hemoptysis.
  • Low iron
  • Eosinophilia
  • Increased serum creatinine level
  • Eleated LDH and CPK
  • Proteinuria
- - - Diffuse, proliferative, necrotizing glomerulonephritis with crescent formation - Biospy 80% of patients have ANCA-positive microscopic polyangiitis
Lupus nephritis - + - - - - + +
  • Foamy dark urine
  • Weight gain
- - - - - Biopsy -
Thin basement membrane disease
Fabry disease - - - - - - + + -
  • Hematuria
  • Proteinuria
- - - Non-specific+/- nephrotic picture - - -
Tubulointerstitial diseases Renal papillary necrosis Flank pain + + + ± Hypotension ±
Acute interstitial nephritis + + +
Analgesic
Nephrolithiasis +
Reflux nephropathy (hydronephrosis) +
Malignancy Renal cell carcinoma (RCC)
Nephroblastoma
Transitional cell carcinoma (TCC)
Prostate cancer
Familial diseases Polycystic kidney disease + - - - - - + +
  • Unilateral or bilateral cysts
  • Hyperdense appearance,
  • Septations
  • Calcifications

Genetic testing demonstrates:

  • Frame insertions/deletions
  • Non-canonical splice site alterations
  • Combined missense changes
  • Interstitial fibrosis
  • Tubular atrophy
  • Thickening and lamellation of tubular basement membranes
  • Microcysts
  • Negative immunofluorescence for complement and immunoglobulin
Ultrasound
Vascular diseases Renal vein thrombosis + + + - - - - -
  • Asymptomatic
  • Abdominal pain
  • Acute in onset
  • Elevation in serum lactate dehydrogenase
  • Cholesterol levels for hypercholesterolemia
  • Albumin levels for hypoalbuminemia
  • Serum complement levels
  • Diagnostic screening
  • Renal venography: Gold standard
Polyarteritis nodosa - -/+ - - - + + -
  • CBC may show:
    • Leukocytosis
    • Normochromic anemia
    • thrombocytosis
Wegner's granulomatosis polyangiitis
Henoch-Schönlein purpura
Lower urinary tract diseases Benign prostatic hyperplasia
Urolithiasis
Interstitial cystitis
Radiogenic cystitis
Systemic diseases Coagulopathy (hemophilia)
Sickle cell anemia
Abdominal aortic aneurysm
Lymphomas
Multiple myeloma
Infectious diseases Pyelonephritis + + + + + + - -
  • Enlarged kidneys

Contrast nephrograms

-
Cystitis - - - + + + - -
  • Presence of a gas in the bladder wall.
  • Also help to detect the presence of a tumor or a stone.
MRI
Prostatitis - + - + + + - -
  • Body aches
  • Focal hypoechoic region located in the peripheral part of the prostate
  • Hyperintense lesions on MRI
  • Neutrophils
  • Between the epithelial cells or inside the stroma.
Urethritis -/- + - + + + - -
  • Urethral discharge

-

  • Diffuse, circumferential urothelial wall thickening and contrast-enhancement
  • Periureteric or perinephric fat stranding.
-
Epididymitis -/+ + + - - -
Cytomegalovirus
Infectious mononucleosis
Condylomata acuminata
Urogenital trauma Inserted bladder or ureteral catheters
Drugs Anticoagulants
Dark urine Hemoglobinuria Autoimmune hemolytic anemia
Microangiopathic hemolytic anemia
Thrombotic thrombocytopenic purpura
Paroxysmal nocturnal hemoglobinuria
Paroxysmal cold hemoglobinuria
Falciparum malaria
Myoglobinuria Crush injury
Vigorous muscle exercise
Hyperthermia (Heat stroke)
Electric shock
Prolonged seizure
Polymyositis
Trichinosis
Haff disease

References

Template:WH Template:WS